Profile for Canada Patent: 2653344
✉ Email this page to a colleague
US Patent Family Members and Approved Drugs for Canada Patent: 2653344
| US Patent Number | US Expiration Date | US Applicant | US Tradename | Generic Name |
|---|---|---|---|---|
| ⤷ Start Trial | Jun 16, 2030 | Astrazeneca Ab | QTERNMET XR | dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride |
| ⤷ Start Trial | Jun 16, 2030 | Astrazeneca Ab | XIGDUO XR | dapagliflozin; metformin hydrochloride |
| ⤷ Start Trial | Jun 16, 2030 | Astrazeneca Ab | FARXIGA | dapagliflozin |
| >US Patent Number | >US Expiration Date | >US Applicant | >US Tradename | >Generic Name |
